Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.

IF 44.5 1区 医学 Q1 CELL BIOLOGY Cancer Cell Pub Date : 2016-07-11 DOI:10.1016/j.ccell.2016.06.005
Stefano Di Biase, Changhan Lee, Sebastian Brandhorst, Brianna Manes, Roberta Buono, Chia-Wei Cheng, Mafalda Cacciottolo, Alejandro Martin-Montalvo, Rafael de Cabo, Min Wei, Todd E Morgan, Valter D Longo
{"title":"Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.","authors":"Stefano Di Biase,&nbsp;Changhan Lee,&nbsp;Sebastian Brandhorst,&nbsp;Brianna Manes,&nbsp;Roberta Buono,&nbsp;Chia-Wei Cheng,&nbsp;Mafalda Cacciottolo,&nbsp;Alejandro Martin-Montalvo,&nbsp;Rafael de Cabo,&nbsp;Min Wei,&nbsp;Todd E Morgan,&nbsp;Valter D Longo","doi":"10.1016/j.ccell.2016.06.005","DOIUrl":null,"url":null,"abstract":"<p><p>Immune-based interventions are promising strategies to achieve long-term cancer-free survival. Fasting was previously shown to differentially sensitize tumors to chemotherapy while protecting normal cells, including hematopoietic stem and immune cells, from its toxic side effects. Here, we show that the combination of chemotherapy and a fasting-mimicking diet (FMD) increases the levels of bone marrow common lymphoid progenitor cells and cytotoxic CD8(+) tumor-infiltrating lymphocytes (TILs), leading to a major delay in breast cancer and melanoma progression. In breast tumors, this effect is partially mediated by the downregulation of the stress-responsive enzyme heme oxygenase-1 (HO-1). These data indicate that FMD cycles combined with chemotherapy can enhance T cell-dependent targeted killing of cancer cells both by stimulating the hematopoietic system and by enhancing CD8(+)-dependent tumor cytotoxicity.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"136-146"},"PeriodicalIF":44.5000,"publicationDate":"2016-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ccell.2016.06.005","citationCount":"259","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2016.06.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 259

Abstract

Immune-based interventions are promising strategies to achieve long-term cancer-free survival. Fasting was previously shown to differentially sensitize tumors to chemotherapy while protecting normal cells, including hematopoietic stem and immune cells, from its toxic side effects. Here, we show that the combination of chemotherapy and a fasting-mimicking diet (FMD) increases the levels of bone marrow common lymphoid progenitor cells and cytotoxic CD8(+) tumor-infiltrating lymphocytes (TILs), leading to a major delay in breast cancer and melanoma progression. In breast tumors, this effect is partially mediated by the downregulation of the stress-responsive enzyme heme oxygenase-1 (HO-1). These data indicate that FMD cycles combined with chemotherapy can enhance T cell-dependent targeted killing of cancer cells both by stimulating the hematopoietic system and by enhancing CD8(+)-dependent tumor cytotoxicity.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
模拟禁食饮食减少HO-1促进T细胞介导的肿瘤细胞毒性。
基于免疫的干预措施是实现长期无癌生存的有希望的策略。先前的研究显示,禁食可以使肿瘤对化疗产生不同程度的敏感性,同时保护正常细胞,包括造血干细胞和免疫细胞,免受化疗毒副作用的影响。在这里,我们发现化疗和模拟禁食饮食(FMD)的结合增加了骨髓普通淋巴样祖细胞和细胞毒性CD8(+)肿瘤浸润淋巴细胞(TILs)的水平,导致乳腺癌和黑色素瘤进展的主要延迟。在乳腺肿瘤中,这种作用部分是由应激反应酶血红素加氧酶-1 (HO-1)的下调介导的。这些数据表明,FMD周期联合化疗可以通过刺激造血系统和增强CD8(+)依赖性肿瘤细胞毒性来增强T细胞依赖性靶向杀伤癌细胞。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Cell
Cancer Cell 医学-肿瘤学
CiteScore
55.20
自引率
1.20%
发文量
179
审稿时长
4-8 weeks
期刊介绍: Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.
期刊最新文献
Targeting STING to generate therapeutic anti-tumor immunity Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications Circulating tumor DNA as a biomarker in early phase clinical trials Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence Mapping the inflammatory origins of lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1